Compare McCormick & Company, Incorporated (MKC) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Moderna, Inc. — how do they compare? McCormick & Company, Incorporated trades at $52.01 (market cap $14.04B), while Moderna, Inc. trades at $59.72 (market cap $23.60B). The key difference: Moderna, Inc. is the larger of the two by market cap, and McCormick & Company, Incorporated pays a 3.68% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MKC | MRNA | |
|---|---|---|
Market Cap | $14.04B | $23.60B |
Sector | Consumer Staples | Health |
52-Week High | $72.81 | $81.80 |
52-Week Low | $45.60 | $22.36 |
Enterprise Value | $18.65B | $19.70B |
Dividend Yield | 3.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $52.35, up 1.26% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 21.91% net margin and 25.7% ROE, supported by recent Q2 2026 earnings beating estimates. Valuation appears attractive with a P/E of 8.69 and P/S of 1.9. The pending Unilever Foods deal, highlighted in recent news (The Motley Fool, 2026-07-07), could transform the business, though organic growth remains modest.
The outlook is cautiously optimistic with 36.7% of analysts rating it Buy and a consensus price target of $59.67 (13.9% upside). Key risks include soft consumer volumes and execution challenges from the Unilever integration. Positive cash flow projections for 2026 and a sustainable dividend enhance appeal, but investors should monitor volume trends and deal progress closely.
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
